You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
入局AD市場 先聲藥業(2096.HK)再創上市新高
格隆匯 06-30 14:04
格隆匯6月30日丨延續近期強勢,先聲藥業(2096.HK)今日繼續走強,盤中一度漲超6%至14.08港元,再創上市新高,市值超360億港元;該股自5月中旬低位至今,累漲超80%。 6月29日,先聲藥業宣佈與德國Vivoryon公司達成合作,在大中華區開發和商業化靶向神經毒性澱粉樣蛋白N3pE(pGlu-Aβ)的阿爾茨海默病 (AD)治療藥物。自此,先聲藥業成為阿爾茨海默病這一巨大市場的入局者。格隆匯援引分析人士稱,先聲藥業成為了最早引入AD創新藥管線的國內企業。自2020年上市以來,先聲藥業在中樞神經市場消息不斷,從對腦卒中單病種、全病程覆蓋,逐步拓展至AD等高挑戰方向,先聲藥業正在形成具有特色護城河的神經領域產品矩陣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account